COMMUNIQUÉS West-GlobeNewswire
-
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
03/11/2025 -
Serina Therapeutics Provides Regulatory Update on SER-252 Program
03/11/2025 -
The Ensign Group Adds Operation in Alabama
03/11/2025 -
Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer
03/11/2025 -
The Ensign Group Expands in Utah
03/11/2025 -
SARMs For Bulking And Cutting Stacks Alternative 2025: Crazy Bulk Launch Legal SARMs For Muscle Growth, Strength & Endurance Supplement.
03/11/2025 -
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
03/11/2025 -
Actimed Therapeutics Further Expands Intellectual Property Portfolio for Lead Compound with New Composition of Matter Patent in Japan
03/11/2025 -
VIVOLTA expands regenerative implant manufacturing capability with dedicated facility
03/11/2025 -
Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna
03/11/2025 -
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
03/11/2025 -
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
03/11/2025 -
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
03/11/2025 -
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
03/11/2025 -
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
03/11/2025 -
IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH
03/11/2025 -
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
03/11/2025 -
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
03/11/2025 -
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
02/11/2025
Pages